HOPKINTON, Mass., Nov. 2, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has launched a new services offering based on a panel of cellular assays that measure the effects of drug candidates on functional activity of proteins called kinases involved in critical cell-signaling pathways. The technology platform and initial panel of nine assays were developed in collaboration with Pfizer Inc. (NYSE: PFE). The new offering, called In-Cell KinaseScreen, is immediately available for compound screening, profiling, and custom assay development services for CDAS' clients, ranging from academia to pharmaceutical companies.
The collaboration between Caliper and Pfizer is focused on developing cellular methods to measure the ability of a compound to inhibit kinase activity. Nine different kinase assays through this collaboration have been developed thus far. The assays can be used early in the drug discovery process to assess compound selectivity, as well as the potential for off-target effects, or unintended inhibition of kinase-controlled pathways other than those against which the drugs were directed. This is important to developing safer drug candidates and reducing late-stage drug attrition. One application of these assays is in the area of oncology, for example, where kinase inhibitors have been used for treating a variety of cancers. These drugs have led to breakthroughs for treating many cancers; however, wider use of such drugs has exposed the potential for serious side effects due to "off-target" activities. Assays that measure kinase functional activity in key pathways in a physiologically relevant cellular context enable oncology researchers, as well as researchers in other therapeutic areas, to better identify compounds that maximize drug target selectivity and minimize potential side effects.
"Caliper is pleased to have collaborated with Pfizer to develop cellular assays designed to enable better compound selectivity, which could lead to improved drug safety evaluation," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "This new assay suite is designed to assist scientists in developing treatments for a wide variety of therapeutic applications with potentially fewer side effects. The In-Cell KinaseScreen is an important addition to our portfolio of products and services for predictive toxicology that are available through our CDAS contract research services division."
A recorded presentation of the Caliper In-Cell KinaseScreen programs and offering by Dr. Rajneesh Uzgare of Caliper's Discovery Alliances and Services (CDAS) business unit is available online at www.caliperLS.com/CDAS. More information on this research collaboration can be obtained from the Caliper website at: CDAS In-cell-kinaseScreen.htm.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper is a registered trademark of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.